Solubility enhancement of Glibenclmide - Bougainvillea nanosuspension for Anti-Diabetic Activity

Abstract

This research sought to improve the solubility and therapeutic effectiveness of Glibenclamide, an anti-diabetic medication with poor water solubility, by creating a nanosuspension formulation that included Bougainvillea spectabilis extract. Glibenclamide, classified as a BCS Class II drug, has limited aqueous solubility, which consequently restricts its dissolution rate and oral bioavailability. The inclusion of Bougainvillea spectabilis, a medicinal plant known for its D-pinitol content and demonstrated anti-diabetic properties, was intended to achieve a combined hypoglycemic effect. The nanosuspension was developed using appropriate stabilizers and excipients to decrease particle size and enhance dispersion stability. The formulation's physicochemical properties, such as particle size, stability, and solubility, were assessed. Phytochemical analysis of the plant extract revealed the presence of active compounds, including flavonoids, phenolics, tannins, alkaloids, glycosides, and other secondary metabolites associated with therapeutic effects. The nanosizing technique enlarged the drug particle surface area, leading to better dissolution and increased drug absorption. The developed Glibenclamide–Bougainvillea nanosuspension exhibited enhanced solubility and is anticipated to improve oral absorption and anti-diabetic effectiveness over the standard formulation. D-pinitol's presence may aid in better glucose control via insulin-sensitizing and insulin-mimetic mechanisms.

Keywords

Introduction

1. Activity of Crude Plant Extracts from Ephedra intermedia Indigenous to Balochistan. The Scientific World Journal. 2017; 2017:1–7. doi:10.1155/2017/5873648.
2. Kumar R, Saha P, Kumar Y, Sahana S, Dubey A, Prakash O. A review on diabetes mellitus: type1 & Type2. World Journal of Pharmacy and Pharmaceutical Sciences. 2020; 9(10):838–50.
3. Kharroubi AT, Darwish HM. Diabetes mellitus: The epidemic of the century. World journal of diabetes. 2015; 6(6):850.
4. Kaul K, Tarr JM, Ahmad SI, Kohner EM, Chibber R. Introduction to Diabetes Mellitus. In: Ahmad SI, editor. Diabetes . New York, NY: Springer New York; 2013 [cited 2026 Feb 24]. p. 1–11. (Advances in Experimental Medicine and Biology).
5. Edelman SV. Type II diabetes mellitus. Advances in internal medicine. 1998;43:449–500.
6. Nie X, Chen Z, Pang L, Wang L, Jiang H, Chen Y, Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds. IJN. 2020 Dec; Volume 15:10215–40. doi:10.2147/IJN.S285134.
7. Patel VR, Agrawal YK. Nanosuspension: An approach to enhance solubility of drugs. Journal of advanced pharmaceutical technology & research. 2011; 2(2):81–7.
8. Velavan S. Phytochemical techniques-a review. World journal of Science and Research. 2015; 1(2):80–91.
9. Azwanida NN. A review on the extraction methods use in medicinal plants, principle, strength and limitation. Med aromat plants. 2015; 4(196):2167–0412.
10. Pena MA. Solubilization and controlled release strategy of poorly water-soluble drugs. Pharmaceuticals. MDPI; 2022 [cited 2026 Feb 24]. p. 1353. Available from: https://www.mdpi.com/1424-8247/15/11/1353.
11. Sreekala MG, Reichal CR, Manju S. Formulation and evaluation of teneligliptin nanosuspension. Research Journal of Pharmacy and Technology. 2024; 17(1):96–102.
12. Perween N, Alshehri S, Easwari TS, Verma V, Faiyazuddin M, Alanazi A, Investigating the feasibility of mefenamic acid nanosuspension for pediatric delivery: Preparation, characterization and role of excipients. Processes. 2021;9 (4):574.